<style face="normal" font="default" size="100%">Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-κB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma</style>

Drupal-Biblio